Procurement of Tocilizumab
About This Opportunity
TranslatedThis tender is for the procurement of Tocilizumab. Tocilizumab is a medication used to treat certain autoimmune conditions, such as rheumatoid arthritis, systemic juvenile idiopathic arthritis, and cytokine release syndrome. It is a monoclonal antibody that inhibits interleukin-6 (IL-6) signaling. The procurement is essential for ensuring that patients suffering from these conditions have access to this important treatment. The tender process will involve selecting a qualified supplier capable of providing Tocilizumab that meets all pharmaceutical quality standards and regulatory requirements. The scope will likely include specific quantities, dosage forms, packaging, and delivery schedules. The objective is to secure a reliable and consistent supply of Tocilizumab to meet patient needs. The evaluation of bids will focus on factors such as product quality, price, supplier reliability, and adherence to regulatory guidelines. This ensures that the procuring entity obtains a critical medication effectively and efficiently.
This is a supplies contract in the health and medical services and information and communication technology sectors, with a focus on Pharmaceuticals. Located in Portugal, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 14,172.
Published through base_gov_pt, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.
Description
Original language: PortugueseThis tender seeks the procurement of Tocilizumab, a medication commonly used in the treatment of various inflammatory and autoimmune conditions. The contracting authority, operating within Portugal, is looking to establish a supply agreement for this critical pharmaceutical product. Tocilizumab, an interleukin-6 receptor inhibitor, plays a vital role in managing diseases such as rheumatoid arthritis, juvenile idiopathic arthritis, and cytokine release syndrome.
The procurement process, managed through Portugal's public procurement portal, BASE, indicates a requirement for qualified suppliers capable of meeting stringent pharmaceutical supply chain standards. Typical requirements for such tenders include demonstrated experience in the supply of high-value, specialized pharmaceuticals, adherence to Good Distribution Practices (GDP), and the ability to ensure consistent and reliable delivery across Portugal. Bidders will likely need to provide detailed product specifications, evidence of regulatory compliance (e.g., European Medicines Agency approvals), and robust quality assurance protocols. Furthermore, proposals may be evaluated on factors such as price, delivery timelines, and the supplier's capacity to manage inventory and respond to fluctuating demand. This tender represents an opportunity for pharmaceutical manufacturers and distributors to engage with the Portuguese healthcare sector and contribute to patient care by providing essential therapeutic agents.
Data provenance
This notice is sourced from base_gov_pt and was originally published on March 12, 2026. Last refreshed 57 days ago. Original language: Portuguese. BidsFactory mirrors official procurement notices and links back to the source for full legal text.
About Unidade Local de Saúde do Alto Alentejo, EPE
Unidade Local de Saúde do Alto Alentejo, EPE has issued 1,113 procurement notices on BidsFactory, including 2 currently open and 1,034 awarded contracts. Activity concentrates in General Supplies & Services, Health & Medical, and Industry & Manufacturing. All notices are published for Portugal. Notices are distributed via base_gov_pt and TED - Tenders Electronic Daily (EU). Most recent publication: June 18, 2026.
Frequently asked questions about this tender
What type of contract is this?
This is a Supplies contract in the Health & Medical sector. The classification helps bidders match the opportunity to their qualifications and registered scope of supply.
What is the estimated budget?
The estimated contract value is Up to €14,172. Bidders should ensure their proposals are consistent with this range and account for any local taxes and contract execution costs.
Where will the contract be performed?
The contract is for delivery in Portugal. Foreign bidders should review local registration, taxation, and any in-country presence requirements before submitting.
How can I submit a bid?
Visit base_gov_pt to access the full notice, required documents, and submission instructions provided by the contracting authority.
Is this tender still open?
No — the contract has already been awarded to ROCHE FARMACÊUTICA QUIMICA, LDA.. The award notice is archived on BidsFactory for transparency and market intelligence.
Who is the contracting authority?
This notice was issued by Unidade Local de Saúde do Alto Alentejo, EPE in Portugal. The authority is responsible for evaluating bids, awarding the contract, and managing performance.
Find tenders like this automatically
Set up alerts and filters that match your business — never miss a relevant opportunity again.